{"id":"adjuvant-temozolomide-tmz","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Headache"},{"rate":"10-30%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL810","moleculeType":"Small molecule","molecularWeight":"194.15"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Temozolomide is a prodrug that is converted into its active form, MTIC, which then methylates DNA, leading to DNA damage and apoptosis in rapidly dividing cells. This mechanism is particularly effective against glioblastoma cells, which have a high rate of proliferation.","oneSentence":"Temozolomide is an alkylating agent that works by interfering with DNA replication and transcription, thereby inhibiting cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:13.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma multiforme"},{"name":"Anaplastic astrocytoma"}]},"trialDetails":[{"nctId":"NCT02152982","phase":"PHASE2, PHASE3","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-15","conditions":"Glioblastoma, Gliosarcoma","enrollment":447},{"nctId":"NCT03197506","phase":"PHASE2","title":"Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-01-15","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":52},{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT07485049","phase":"EARLY_PHASE1","title":"Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors","status":"NOT_YET_RECRUITING","sponsor":"Nader Sanai","startDate":"2026-04","conditions":"Glioblastoma (GBM)","enrollment":78},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":"Glioblastoma, GBM","enrollment":103},{"nctId":"NCT03663725","phase":"PHASE3","title":"Treatment Intensification With Temozolomide in Adults With a Glioblastoma","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-13","conditions":"Glioblastoma","enrollment":486},{"nctId":"NCT02287428","phase":"PHASE1","title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Glioblastoma","enrollment":56},{"nctId":"NCT06202066","phase":"PHASE2","title":"Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm","enrollment":60},{"nctId":"NCT06504381","phase":"PHASE1, PHASE2","title":"DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-01-08","conditions":"High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma","enrollment":70},{"nctId":"NCT07452458","phase":"PHASE3","title":"Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2026-06-08","conditions":"Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma","enrollment":398},{"nctId":"NCT07195591","phase":"PHASE3","title":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","status":"RECRUITING","sponsor":"GT Medical Technologies, Inc.","startDate":"2025-12-10","conditions":"Glioblastoma","enrollment":766},{"nctId":"NCT02455557","phase":"PHASE2","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2015-05-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":66},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT04765514","phase":"PHASE2","title":"Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2022-07-27","conditions":"Glioblastoma Multiforme","enrollment":107},{"nctId":"NCT03405792","phase":"PHASE2","title":"Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-23","conditions":"Glioblastoma, Glioblastoma, WHO Grade IV","enrollment":40},{"nctId":"NCT05635734","phase":"PHASE1, PHASE2","title":"Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cantex Pharmaceuticals","startDate":"2023-09-05","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT06388733","phase":"PHASE3","title":"A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma","status":"RECRUITING","sponsor":"Ivy Brain Tumor Center","startDate":"2024-06-19","conditions":"Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant","enrollment":450},{"nctId":"NCT05781321","phase":"PHASE2","title":"Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-03-23","conditions":"Glioblastoma","enrollment":170},{"nctId":"NCT07365280","phase":"PHASE2","title":"Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"ZSky Biotech Inc","startDate":"2026-01-09","conditions":"Glioblastoma","enrollment":78},{"nctId":"NCT04216329","phase":"PHASE1","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-07","conditions":"Gliosarcoma, Newly Diagnosed, Glioblastoma","enrollment":11},{"nctId":"NCT00887146","phase":"PHASE3","title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Brain and Central Nervous System Tumors","enrollment":305},{"nctId":"NCT02179086","phase":"PHASE2","title":"Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2014-12-04","conditions":"Glioblastoma","enrollment":606},{"nctId":"NCT06095375","phase":"PHASE1","title":"Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2022-07-04","conditions":"Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma","enrollment":21},{"nctId":"NCT05040360","phase":"PHASE2","title":"Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-05-05","conditions":"Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":141},{"nctId":"NCT02344355","phase":"PHASE2","title":"A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bryan Allen","startDate":"2017-03-13","conditions":"Glioblastoma Multiforme","enrollment":90},{"nctId":"NCT04900792","phase":"PHASE1","title":"A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bryan Allen","startDate":"2023-02-28","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":17},{"nctId":"NCT03687957","phase":"PHASE1, PHASE2","title":"rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-01-04","conditions":"Glioma","enrollment":42},{"nctId":"NCT04945148","phase":"PHASE2","title":"Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2024-05-10","conditions":"Glioblastoma, IDH-wildtype","enrollment":640},{"nctId":"NCT04250922","phase":"PHASE2, PHASE3","title":"LAM561 With RT and TMZ for Adults With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laminar Pharmaceuticals","startDate":"2019-12-01","conditions":"Primary Glioblastoma, Glioblastoma Multiforme","enrollment":144},{"nctId":"NCT06072586","phase":"EARLY_PHASE1","title":"A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions","status":"RECRUITING","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2023-10-18","conditions":"High Grade Glioma, Glioblastoma","enrollment":82},{"nctId":"NCT03746080","phase":"PHASE2","title":"Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma","status":"COMPLETED","sponsor":"Lawrence D Recht","startDate":"2018-12-04","conditions":"Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma","enrollment":21},{"nctId":"NCT06831526","phase":"EARLY_PHASE1","title":"Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-11-06","conditions":"Glioblastoma","enrollment":12},{"nctId":"NCT07223034","phase":"PHASE1","title":"A Study of 177Lu-PSMA-617 in People With Gliomas","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-27","conditions":"Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype","enrollment":20},{"nctId":"NCT04555577","phase":"PHASE1","title":"Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-09-20","conditions":"Glioblastoma, Gliosarcoma","enrollment":29},{"nctId":"NCT04373785","phase":"PHASE1, PHASE2","title":"NG101m Adjuvant Therapy in Glioblastoma Patients","status":"NOT_YET_RECRUITING","sponsor":"NeuGATE Theranostics","startDate":"2027-01-01","conditions":"Glioblastoma Multiforme","enrollment":52},{"nctId":"NCT03535350","phase":"PHASE1","title":"Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2018-08-24","conditions":"Glioblastoma","enrollment":36},{"nctId":"NCT03174197","phase":"PHASE1, PHASE2","title":"Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-30","conditions":"Glioblastoma, Gliosarcoma","enrollment":60},{"nctId":"NCT05342883","phase":"PHASE4","title":"GammaTile and Stupp in Newly Diagnosed GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"GT Medical Technologies, Inc.","startDate":"2022-08-17","conditions":"Glioblastoma","enrollment":61},{"nctId":"NCT05190315","phase":"PHASE1","title":"Chlorpromazine and Standard of Care in Glioblastoma","status":"COMPLETED","sponsor":"Mohammed Milhem","startDate":"2022-01-28","conditions":"Glioblastoma Multiforme","enrollment":10},{"nctId":"NCT02717962","phase":"PHASE2","title":"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting","status":"COMPLETED","sponsor":"Kintara Therapeutics, Inc.","startDate":"2017-01-20","conditions":"Glioma, Glioblastoma, Glioblastoma Multiforme","enrollment":118},{"nctId":"NCT04747145","phase":"PHASE2","title":"Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-06-03","conditions":"Glioblastoma","enrollment":38},{"nctId":"NCT05929495","phase":"PHASE2","title":"Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma","status":"RECRUITING","sponsor":"University of Milano Bicocca","startDate":"2024-02-12","conditions":"Glioblastoma, IDH-wildtype, Metformin, Malignancies","enrollment":25},{"nctId":"NCT07047066","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-07-10","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT03345095","phase":"PHASE3","title":"A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2018-07-26","conditions":"Newly Diagnosed Glioblastoma","enrollment":749},{"nctId":"NCT04477200","phase":"PHASE1","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-08-05","conditions":"Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV","enrollment":68},{"nctId":"NCT02780024","phase":"PHASE2","title":"Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-03","conditions":"Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT06428045","phase":"PHASE1","title":"STARLITE for Unresectable High-Grade Gliomas","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-04-15","conditions":"High Grade Glioma","enrollment":24},{"nctId":"NCT02655601","phase":"PHASE1, PHASE2","title":"Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001","status":"COMPLETED","sponsor":"BioMimetix JV, LLC","startDate":"2018-09-25","conditions":"High Grade Glioma, Astrocytoma, Grade III, Glioblastoma","enrollment":177},{"nctId":"NCT01777919","phase":"PHASE2","title":"Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform","status":"NOT_YET_RECRUITING","sponsor":"Olympion Medical Center","startDate":"2027-01","conditions":"Glioblastoma Multiforme","enrollment":32},{"nctId":"NCT01430351","phase":"PHASE1","title":"Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-09-14","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":144},{"nctId":"NCT02715609","phase":"PHASE1, PHASE2","title":"Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-06-15","conditions":"Glioblastoma Multiforme","enrollment":35},{"nctId":"NCT03576612","phase":"PHASE1","title":"GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2018-02-27","conditions":"Glioma, Malignant","enrollment":41},{"nctId":"NCT04881032","phase":"PHASE1, PHASE2","title":"AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Jean Perrin","startDate":"2022-03-07","conditions":"Glioblastoma","enrollment":66},{"nctId":"NCT04968366","phase":"PHASE1","title":"Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-07-30","conditions":"Glioblastoma Multiforme of Brain","enrollment":11},{"nctId":"NCT04397679","phase":"PHASE1","title":"Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2021-08-12","conditions":"Glioblastoma, Gliosarcoma","enrollment":2},{"nctId":"NCT04421378","phase":"PHASE1, PHASE2","title":"A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-06-08","conditions":"Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT04195139","phase":"PHASE2","title":"Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2018-02-22","conditions":"Glioblastoma Multiforme","enrollment":103},{"nctId":"NCT03395587","phase":"PHASE2","title":"Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2018-03-06","conditions":"Glioblastoma","enrollment":136},{"nctId":"NCT05768919","phase":"PHASE1, PHASE2","title":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","status":"RECRUITING","sponsor":"SignPath Pharma, Inc.","startDate":"2023-03-03","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT06012695","phase":"PHASE1, PHASE2","title":"NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Novelwise Pharmaceutical Corporation","startDate":"2023-08-11","conditions":"Malignant Neoplasm, Malignant Neoplasm of Brain","enrollment":79},{"nctId":"NCT01985087","phase":"PHASE1, PHASE2","title":"A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Louisville","startDate":"2014-09","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT03363659","phase":"PHASE2","title":"Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-03-28","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":15},{"nctId":"NCT03234595","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma","status":"COMPLETED","sponsor":"Everfront Biotech Co., Ltd.","startDate":"2017-11-01","conditions":"Recurrent GBM","enrollment":22},{"nctId":"NCT06595186","phase":"PHASE2","title":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","status":"RECRUITING","sponsor":"JenKem Technology Co., Ltd.","startDate":"2022-10-31","conditions":"Glioblastoma Multiforme (GBM)","enrollment":25},{"nctId":"NCT06353360","phase":"PHASE2","title":"TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.","status":"RECRUITING","sponsor":"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","startDate":"2024-04-30","conditions":"Glioblastoma Multiforme","enrollment":30},{"nctId":"NCT06524063","phase":"PHASE1","title":"Targeted Survivin DC Cell Injection for the Treatment of GBM","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tricision Biotherapeutics Inc","startDate":"2024-08-01","conditions":"Glioblastoma","enrollment":9},{"nctId":"NCT06346821","phase":"","title":"Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data","status":"COMPLETED","sponsor":"Sichuan University","startDate":"2022-11-22","conditions":"Glioblastoma Multiforme","enrollment":181},{"nctId":"NCT03776071","phase":"PHASE3","title":"A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2020-12-16","conditions":"Glioblastoma","enrollment":260},{"nctId":"NCT02085304","phase":"PHASE1, PHASE2","title":"Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM","status":"TERMINATED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2013-05-07","conditions":"Glioblastoma","enrollment":8},{"nctId":"NCT03927222","phase":"PHASE2","title":"Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma","status":"TERMINATED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2019-09-30","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT00589875","phase":"PHASE2","title":"Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2007-03","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":52},{"nctId":"NCT03466450","phase":"PHASE1, PHASE2","title":"Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2018-03-15","conditions":"Glioblastoma","enrollment":75},{"nctId":"NCT06297512","phase":"PHASE2","title":"Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).","status":"RECRUITING","sponsor":"Iacopo Sardi","startDate":"2022-12-09","conditions":"Glioblastoma","enrollment":20},{"nctId":"NCT02432417","phase":"PHASE2","title":"The Addition of Chloroquine to Chemoradiation for Glioblastoma,","status":"WITHDRAWN","sponsor":"Maastricht Radiation Oncology","startDate":"2023-11-10","conditions":"Glioblastoma, Astrocytoma, Grade IV","enrollment":""},{"nctId":"NCT03425292","phase":"PHASE1","title":"A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2018-03-01","conditions":"Newly Diagnosed High Grade Glioma","enrollment":49},{"nctId":"NCT03463265","phase":"PHASE2","title":"Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Aadi Bioscience, Inc.","startDate":"2018-08-01","conditions":"High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma","enrollment":62},{"nctId":"NCT00626990","phase":"PHASE3","title":"Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-12","conditions":"Brain and Central Nervous System Tumors","enrollment":751},{"nctId":"NCT00482677","phase":"PHASE3","title":"Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2007-11-14","conditions":"Brain and Central Nervous System Tumors","enrollment":562},{"nctId":"NCT04967690","phase":"PHASE1","title":"A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM","status":"UNKNOWN","sponsor":"Double Bond Pharmaceutical AB","startDate":"2024-01","conditions":"Newly Diagnosed Glioblastoma","enrollment":27},{"nctId":"NCT04757662","phase":"PHASE1","title":"Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-05-14","conditions":"Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV","enrollment":18},{"nctId":"NCT02366728","phase":"PHASE2","title":"DC Migration Study for Newly-Diagnosed GBM","status":"COMPLETED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2015-10-12","conditions":"Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma","enrollment":64},{"nctId":"NCT03623347","phase":"","title":"Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2011-01-01","conditions":"Chemoradiotherapy","enrollment":70},{"nctId":"NCT02573324","phase":"PHASE3","title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-01-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":691},{"nctId":"NCT00582075","phase":"PHASE2","title":"Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2002-07","conditions":"Cancer, Brain Metastases","enrollment":25},{"nctId":"NCT01822275","phase":"PHASE2","title":"Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2013-05","conditions":"Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)","enrollment":24},{"nctId":"NCT04851834","phase":"PHASE1, PHASE2","title":"NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma","status":"TERMINATED","sponsor":"Xennials Therapeutics Australia Pty Ltd","startDate":"2021-08-25","conditions":"Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma","enrollment":12},{"nctId":"NCT05031975","phase":"PHASE2","title":"Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2022-05-02","conditions":"Colorectal Cancer","enrollment":35},{"nctId":"NCT04926168","phase":"","title":"6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-03-01","conditions":"MGMT-Methylated Glioblastoma","enrollment":""},{"nctId":"NCT01062425","phase":"PHASE2","title":"Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-02-26","conditions":"Adult Glioblastoma, Adult Gliosarcoma","enrollment":261},{"nctId":"NCT01062399","phase":"PHASE1, PHASE2","title":"Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2010-12","conditions":"Brain and Central Nervous System Tumors","enrollment":279},{"nctId":"NCT04614493","phase":"PHASE2","title":"Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-11","conditions":"Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type), Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide","enrollment":66},{"nctId":"NCT00112502","phase":"PHASE2","title":"Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Brain and Central Nervous System Tumors, Glioblastoma Multiforme","enrollment":178},{"nctId":"NCT03906448","phase":"PHASE2","title":"FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma","status":"TERMINATED","sponsor":"University of Florida","startDate":"2019-05-20","conditions":"Astrocytoma, Grade II, Astrocytoma, Grade III","enrollment":1},{"nctId":"NCT01120639","phase":"PHASE1, PHASE2","title":"Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-04","conditions":"Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme","enrollment":30},{"nctId":"NCT02046187","phase":"PHASE1, PHASE2","title":"Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma","status":"TERMINATED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2013-10","conditions":"Glioblastoma (GBM)","enrollment":14},{"nctId":"NCT02903069","phase":"PHASE1","title":"Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-08-17","conditions":"Glioblastoma, Malignant Glioma","enrollment":66},{"nctId":"NCT04829097","phase":"PHASE3","title":"Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-11-01","conditions":"Glioblastoma","enrollment":80},{"nctId":"NCT04583020","phase":"PHASE2","title":"Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-11-12","conditions":"Glioblastoma","enrollment":42},{"nctId":"NCT01390948","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-10-18","conditions":"High Grade Glioma","enrollment":124},{"nctId":"NCT00304031","phase":"PHASE3","title":"Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2006-01","conditions":"Brain and Central Nervous System Tumors","enrollment":1173}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":696,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"adjuvant temozolomide (TMZ)","genericName":"adjuvant temozolomide (TMZ)","companyName":"Alliance for Clinical Trials in Oncology","companyId":"alliance-for-clinical-trials-in-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Temozolomide is an alkylating agent that works by interfering with DNA replication and transcription, thereby inhibiting cancer cell growth. Used for Glioblastoma multiforme, Anaplastic astrocytoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}